|
Nov 7
|
Nektar: Q3 Earnings Snapshot
|
|
Nov 7
|
Nektar Therapeutics Reports Third Quarter 2024 Financial Results
|
|
Nov 7
|
Nektar and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 for the Treatment of Radiation Induced Lymphopenia in Locally Advanced Non-Small Cell Lung Cancer Patients at Society for Immunotherapy of Cancer (SITC) Annual Meeting
|
|
Nov 6
|
Nektar Therapeutics to Participate in Upcoming Investor Conferences
|
|
Nov 5
|
Nektar Therapeutics to sell Alabama facility to Ampersand
|
|
Nov 4
|
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
|
|
Nov 4
|
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama
|
|
Oct 31
|
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
|
|
Oct 29
|
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases
|
|
Oct 17
|
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination with Autologous CD19-22 CAR-T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
|
|
May 10
|
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
|
|
May 10
|
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
|
|
May 10
|
Q1 2024 Nektar Therapeutics Earnings Call
|
|
May 9
|
Nektar Therapeutics Reports First Quarter 2024 Financial Results
|